Ra Pharmaceuticals
Closed portfolio with an early-phase archive tilt
According to ClinicalTrials.gov-derived indexes, Ra Pharmaceuticals sits in the upper quartile of US sponsors by registered trial count (#2,411 of 15,742 sponsors by registered trial count).
Ra Pharmaceuticals: 5 sponsored US clinical trials, none currently recruiting.
Ra Pharmaceuticals sponsors 5 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 3 completed. 1 of these trials are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Generalized Myasthenia Gravis, with 1 trials.
Upper-quartile sponsor footprint
Ra Pharmaceuticals sits in the upper quartile of the sponsor corpus (#2,411 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Indexed trials (enrollment closed)
5 total, page 1 of 1
Safety and Efficacy Study of Zilucoplan in Subjects With Immune-Mediated Necrotizing Myopathy
NCT04025632
Safety, Tolerability, and Efficacy of Zilucoplan in Subjects With Generalized Myasthenia Gravis
NCT04115293
Safety and Efficacy Study of RA101495 in Subjects With Generalized Myasthenia Gravis
NCT03315130
Extension Study of RA101495 for Patients With PNH Who Have Completed a Zilucoplan (RA101495) Clinical Study
NCT03225287
Phase 2 Safety and Efficacy Study of Zilucoplan (RA101495) to Treat PNH Patients Who Have an Inadequate Response to Eculizumab
NCT03030183
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 4 |
| Phase 3 | 1 |
Therapeutic Areas
How the Ra Pharmaceuticals early-phase archive is shaped
5 indexed studies, none listed as recruiting (0% open); 3 completed (60%).
Phase mix: 1 late (III/IV) vs 4 early (I/II) (early-phase heavy).
Top condition: Generalized Myasthenia Gravis (1 trial), 0 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Ra Pharmaceuticals: archived-pipeline peers nationwide
Peers matched on 5 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Ra Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 5 archived trials
- 4YouandMe · 5 trials · 0% recruiting
- Abbott Rapid Dx · 5 trials · 0% recruiting
- Access Business Group · 5 trials · 0% recruiting
- Acera Surgical · 5 trials · 20% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this Ra Pharmaceuticals page
5 registered trials is a research-attention snapshot, not an endorsement of Ra Pharmaceuticals or any single study.
- None of Ra Pharmaceuticals's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Generalized Myasthenia Gravis is the condition Ra Pharmaceuticals studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Generalized Myasthenia Gravis trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Ra Pharmaceuticals pipeline card: 5 registered trials from official public datasets.Report a data error.